1. Home
  2. Medical Research
  3. Charleston, SC
  4. Saras Cure

Saras Cure

  • Charleston, SC
  • Tax-exempt since 2018
  • EIN: 82-5445706
sarascure.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate

Organization summary

Saras Cure is a 501(c)(3) organization, classified under Medical Research (NTEE H30). Contributions are tax-deductible.

783 Stiles Dr, Charleston, SC 29412-5071

In fiscal year 2024 it reported $91,784 in revenue and $104,700 in expenses, with contributions making up 37.6% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2022 Form 990

Special events other expenses 17,915 taxes/licenses 80 islands against cancer 7,551 expenses advertising and website 11,794 marketing materials 4,239 bank & credit card fees 66 supplies 1,023 travel 22,172 other expenses 104 total 64,944

Main program · fiscal year 2022

  • Sara's cure is the only non-profit representing clear cell sarcoma in the USA but we collaborate with others throughout the world to ensure our work is efficient, meaningful and impactful to the ccs family of patients and our champion clinicians. Throughout 2021 we have continued funding repurposed drug testing by working with our medical advisors and their labs. Our executive director serves on a… Read more

    Sara's cure is the only non-profit representing clear cell sarcoma in the USA but we collaborate with others throughout the world to ensure our work is efficient, meaningful and impactful to the ccs family of patients and our champion clinicians. Throughout 2021 we have continued funding repurposed drug testing by working with our medical advisors and their labs. Our executive director serves on an fda repurposed drug testing task force that meets monthly. This strategic involvement with key leaders ensures that the time and money spent is put to its highest and best use. In November 2021 the first of its kind phase I/II ccs trial opened. This was done in collaboration with rafael (now cornerstone pharma), the fda, and most important the ccs family of patients. We partnered to do this by agreeing to provide financial support to patients in the form of travel reimbursement to help patients get to trial locations. We hired the national organization of rare disorders to manage the disbursement of funds to the ccs patients directly. We have helped several patients to date. The clinical trial is ongoing. We continue to build the registry with nord and finalized the data dictionary in dec 2021. We continue to support patients through referrals to sarcoma centers of excellence and to the doctors that champion the ccs research who work with us to support our mission. We attended the world orphan drug congress in August 2021 and had a ccs father/board member attend as well as our executive and scientific directors who also attended the nord and ctos sarcoma conferences virtually. The ccs family of patients continues to be the driving force within the organization and has been critical to actively and financially supporting the work we do by participating in focus groups, providing patient experience input and hosting fundraisers in their communities around the globe including online events and facebook fundraisers.

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$91,784Fiscal year 20242022: $99,90620222024: $91,7842024
Expenses$104,700Fiscal year 20242022: $105,12920222024: $104,7002024
Total assets—Fiscal year 2024
Total liabilities—Fiscal year 2024
Fiscal year ending December 2024
Revenue$91,784
Expenses$104,700
Net income−$12,916
Net assets$51,801

Notable sources of revenue

Percent of total revenue
Contributions$34,473
Program services—
Investment income$3
Other (net)$57,308

Assets / debt

Total assets—
Total liabilities—
Net assets$51,801

Compensation

Not in our extract for this year.

Fiscal year ending December 2022
Revenue$99,906
Expenses$105,129
Net income−$5,223
Net assets$91,017

Notable sources of revenue

Percent of total revenue
Contributions$83,212
Program services—
Investment income$1
Other (net)$16,693

Assets / debt

Total assets—
Total liabilities—
Net assets$91,017

Compensation

Not in our extract for this year.

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?